Dow Biomedica and Seoul Wirye Bio Long-Term Care Hospital Establish Collaborative Model for Liquid Biopsy–Based MRD Monitoring in Cancer Survivors

2026.02.09

From Complete Response to MRD: A Paradigm Shift in Multiple Myeloma Treatment Evaluation

2026.02.03

Asia-Pacific Joint Symposium Highlights Clinical Implications of ctDNA-Based MRD in Solid Tumors

2026.01.20

Blood-Based Detection of Colorectal Cancer… A Shift in the Screening Paradigm?

2026.01.13

FDA Approves IsoPSA as an Adjunct Test for Prostate Cancer Diagnosis, Potentially Reducing the Need for Biopsy

2025.12.15

Rare Disease Diagnosis Shifts from Single-Gene Testing to the NGS Era

2025.12.09

Automated Mass Spectrometry System Receives FDA 510(k) Clearance, with Plans for Introduction in Korea

2025.11.17

Dow Biomedica and 10x Genomics Spotlight the Future of Precision Cell Therapy at KSGCT 2025

2025.11.10

Unveiling a Technology for Early Prediction of Multiple Myeloma Relapse

2025.11.04

Early Prediction of Colorectal Cancer Recurrence Through a Blood Test

2025.07.30

Shield Blood Test Added to U.S. NCCN Guidelines as Korean Launch Nears

2025.07.15

NGS to Reduce Infectious Disease Diagnosis from 33 Days to 3 — Clinical Application Imminent

2025.07.01